SDB-006 is a drug that acts as a potent agonist for the cannabinoid receptors, with an EC<sub>50</sub> of 19 nM for human CB<sub>2</sub> receptors, and 134 nM for human CB<sub>1</sub> receptors. It was discovered during research into the related compound SDB-001 which had been sold illicitly as "2NE1". SDB-006 metabolism has been described in literature.